Effects of tibolone on bone quality in ovariectomized monkeys

Menopause

Volumn 12, Issue 5, 2005, Pages 613-618

  Lees, Cynthia J ^a   Ederveen, Antwan G H ^b   Spanjers, Cees P M ^b   Clarkson, Thomas B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NV ORGANON   (Netherlands)

Author keywords

Biomarkers; Bone strength; CEE; Monkeys; MPA; Tibolone

Indexed keywords

BIOLOGICAL MARKER; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; TIBOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE STRENGTH; BONE TISSUE; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LIPID DIET; LUMBAR VERTEBRA; MONKEY; NONHUMAN; OVARIECTOMY; RISK ASSESSMENT;

ALKALINE PHOSPHATASE; ANIMALS; BIOMECHANICS; BONE DENSITY; BONE REMODELING; CONTRACEPTIVE AGENTS, FEMALE; DIETARY FATS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FEMUR; LUMBAR VERTEBRAE; MACACA FASCICULARIS; MEDROXYPROGESTERONE 17-ACETATE; NORPREGNENES; OVARIECTOMY; RANDOM ALLOCATION;

EID: 25444532508     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000179951.87233.f4     Document Type: Article

References (20)

1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
3. Mason JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
4. Kloosterboer HJ. Tibolone: a steroid with tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-238.
5. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-2422.
6. Gallagher JC, Bay link DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-4726.
7. Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17 beta-estradiol and dydrogesterone. J Bone Miner Res 1997;12:806-812.
8. Ederveen AGH, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 2001;16:1651-1657.
9. Ederveen AGH, Spanjers CPM, Quaijtaal JHM, Kloosterboer HJ. Effects of 16 months of treatment with tibolone on bone mass, turnover, and biomechanical quality in mature ovariectomized rats. J Bone Miner Res 2001;16:1674-1681.
10. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001;86:5396-5404.
11. Brommage R, Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 1999;84:3757-3763.
12. Jerome CP, Carlson CS, Register TC, Bain FT, Jayo MJ, Weaver DS, Adams MR. Bone functional changes in intact, ovariectomized, and ovariectomized, hormone-supplemented adult cynomolgus monkeys (Macaco fascicularis) evaluated by serum biomarkers and dynamic histomorphometry. J Bone Miner Res 1994;9:527-540.
13. Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP. Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 2002;9:320-328.
14. Turner CH, Burr DB. Basic biomechanical measurements of bone: A tutorial. Bone 1993;14:595-608.
15. Brommage R. Perspectives on using nonhuman primates to understand the etiology and treatment of postmenopausal osteoporosis. J Musculoskel Neuron Interact 2001;1:307-325.
16. Rymer J, Chapman MG, Fogelman I. Effects of tibolone on postmenopausal bone loss. Osteoporos Int 1994;4:314-319.
17. Berning B, van Kuijk C, Kuiper JW, Coelingh Bennink HJ, Fauser BC. Increased loss of trabecular but not cortical bone density after discontinuation of 2 years hormone replacement therapy with tibolone. Maturitas 1999;31:151-159.
18. Kuiper JW, van Kuijk C, Grashuis JL, Ederveen AG, Schutte HE. Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro. Osteoporos Int 1996;6:25-30.
19. Pavlov PW, Ginsburg J, Kicovic PM, van der Schaaf DB, Prelevic G, Bennink HJ. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol Endocrinol 1999;13:230-237.
20. European Menopause Society. European consensus development conference on menopause. Hum Reprod 1996;11:975-979.